Clinical trial · no report yet · Phase 3
NCT05468489
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
- NCT05468489 ↗
- Active, not recruiting
- Shanghai Henlius Biotech
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Bluesky threads | 2 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Open-label Study of Serplulimab Plus Chemotherapy (Carboplatin-Etoposide) in Comparison With Atezolizumab Plus Chemotherapy in Previously Untreated US Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ASTRIDE)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Extensive Stage Small Cell Lung Cancer
- Interventions
- Serplulimab + chemotherapy (carboplatin-etoposide); Atezolizumab + chemotherapy (carboplatin-etoposide)
- Arms
- Serplulimab + chemotherapy · Experimental
- Atezolizumab + chemotherapy · Active comparator
- Enrollment
- 200 (estimated)
- Primary outcomes
- OS
- Sponsor
- Shanghai Henlius Biotech
- Start
- Nov 18, 2022
- Primary completion
- Feb 28, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT05468489 · updated Oct 21, 2025